What is LumaCyte?
LumaCyte operates at the forefront of bioanalytics, developing and producing label-free, single-cell analysis and sorting instrumentation. Their proprietary Laser Force Cytology (LFC) technology measures intrinsic cellular properties without the need for antibody or genetic labeling. This innovative approach generates multivariate data, enabling sophisticated Big Data strategies and cloud computing for advanced analytics. LumaCyte's platform finds critical applications across various sectors, including vaccine development, cell and gene therapy, cancer research, CAR T-cell immunotherapy, adventitious agent testing, and pre-clinical drug discovery, as well as biomanufacturing quality control and process optimization.
How much funding has LumaCyte raised?
LumaCyte has raised a total of $327K across 2 funding rounds:
Debt
$150K
Debt
$177K
Debt (2020): $150K with participation from PPP
Debt (2021): $177K led by PPP
What's next for LumaCyte?
With a substantial capital base indicated by $327K, LumaCyte is positioned for continued expansion and technological advancement. The company's focus on label-free single-cell analysis, particularly through its Laser Force Cytology platform, addresses critical needs in biopharmaceutical development and manufacturing. Future strategic initiatives are likely to involve scaling production, enhancing analytical capabilities, and broadening the application scope of their technology to capture emerging opportunities in areas like personalized medicine and advanced diagnostics. The recent financing, though undisclosed in amount, signals ongoing investor confidence in LumaCyte's disruptive potential and its capacity to drive innovation in biological systems understanding.
See full LumaCyte company page
